Forte Biosciences Insider Sell‑Offs Tie Up Merger, Directors Dump Millions of Shares in One Day
Forte’s merger with argenx triggers mass insider sales—compliance, not panic. Investors should view the exit as a clean transition into argenx’s oncology pipeline.
7 minutes to read
